Monoclonal antibody B43 Genistein-conjugate

Drug Profile

Monoclonal antibody B43 Genistein-conjugate

Alternative Names: B43-Gen; B43-Genistein; B43-Genistein conjugate; Monoclonal antibody B43-Gen

Latest Information Update: 18 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Minnesota
  • Developer Bristol-Myers Squibb; University of Minnesota
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Feb 2000 Clinical data have been added to the therapeutic trials section
  • 29 Mar 1999 A phase I study has been added to the pharmacokinetics, adverse events and therapeutic trials sections
  • 22 Mar 1999 Phase-I clinical trials for Acute lymphoblastic leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top